Abstract 493P
Background
Epidermal growth factor receptor (EGFR) deletion of exon 19 and exon 21 mutations are the most common mutations in advanced non-small cell lung cancer (NSCLC) and predict higher sensitivity to EGFR tyrosine kinase inhibitors (TKI). The present study is a retrospective analysis of patients harboring EGFR exon 19 deletions and exon 21 mutations in advanced NSCLC.
Methods
Data of patients diagnosed with advanced NSCLC patients with EGFR mutations from January 2012 to March 2019 was analysed. EGFR mutation analysis was performed using DNA sequencing by real time polymerase chain reaction method. Exon 19 and exon 21 mutated patients were compared for clinicopathological features and outcomes.
Results
Data of 697 patients with lung cancer was retrieved of which 613 patients had advanced NSCLC. A total of 441 patients were evaluated for EGFR mutations and 135 (30.6%) patients were positive for EGFR mutations. The median age at presentation was 57.5 years(range, 30-88). Smoking history was seen in 38 (28.1%) patients and 97 (71.8%) were non smokers. Of these 135 patients with EGFR positivity, 129(95.6%) had adenocarcinoma histology and 6(4.4%) had adenosquamous histology. Exon 19 and exon 21 mutations accounted for 79(58.5%) and 45(33.33%) cases respectively. Mutations in exon 18, exon 20 and double mutations were seen in 2(1.4%), 3(2.2%) and 6(4.4%) patients respectively. Thirty nine (28.8%) patients received initial chemotherapy followed by switch maintenance. Geftinib (82.2%) was the most common TKI used followed by erlotinib (9.6%), Afatinib (4.5%), Osimeritinib (0.8%) and chemotherapy (2.9%). The clinical profile, treatment details and outcomes are tabulated below. The median PFS and OS were 8.9 months (range, 4-42 months) and 18 months (range,4-46 months) respectively.
Table: 493P
Overall EGFR Positive(n = 135) | Exon 19 deletions(n = 79) | Exon 21 Mutated (n = 45) | P Value | |
---|---|---|---|---|
Median Age (years) | 57.5 (range, 30-88) | 55 (range, 35-88) | 61 (range, 30-80) | |
Sex: Male Female Ratio | 75 60 1.25:1 | 44 35 1.25:1 | 25 20 1.25:1 | 0.98 |
Smoker: Yes No | 38 97 | 26 53 | 11 34 | 0.32 |
Metastases: Bone B/L lung Pleural effusion Brain Liver | 67 58 40 22 10 | 39 32 22 20 8 | 26 22 13 2 1 | 0.36 0.38 0.9 0.03 0.24 |
Rash Grade 1 Grade 2 Grade 3 | 37 20 10 7 | 23 8 10 5 | 13 11 0 2 | 0.8 |
Response evaluated Partial response Stable disease Progressive disease | 111 48 (43.3%) 49 (44.1%) 14 (12.6%) | 65 27 (41.6%) 31 (47.7%) 7 (10.7%) | 38 18 (47.4%) 16 (42.1%) 4 (10.5%) | 0.5 0.6 0.7 |
Median PFS (months) | 8.9 | 9.2 | 8.3 | 0.8 |
Median OS (months) | 18 | 18.9 | 17 | 0.5 |
Conclusions
In patients with EGFR-sensitizing mutations, tyrosine kinase inhibitors offer superior progression free survival and response rates and are well tolerated. Brain metastases at presentation were significantly higher in exon 19 compared to exon 21. No significant differences were observed in median PFS or median OS in EGFR exon 19 deleted or Exon 21 mutated subgroup.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Medical Oncology, Nizam\'s Institute of Medical Sciences.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
164P - Multi-centered phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant advanced gastric cancer (HGCSG1502)
Presenter: Yusuke Sasaki
Session: Poster display session
Resources:
Abstract
165P - Lenvatinib treatment for advanced hepatocellular carcinoma: The relationship between efficacy and safety
Presenter: Takayoshi Oikawa
Session: Poster display session
Resources:
Abstract
166P - The comparison between UGT1A1 single heterozygous and wild type regarding the clinical outcomes of fixed dose irinotecan monotherapy for advanced gastric cancer: Multicenter retrospective study
Presenter: Takahide Sasaki
Session: Poster display session
Resources:
Abstract
167P - Prognostic impact of the C-reactive protein/albumin ratio in advanced pancreatic cancer treated with GEM plus nab-PTX or FOLFIRINOX: Based on the results of a multicenter retrospective study (the NAPOLEON study)
Presenter: Akitaka Makiyama
Session: Poster display session
Resources:
Abstract
168P - A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of Glasgow Prognostic Score (GPS)
Presenter: Takuya Honda
Session: Poster display session
Resources:
Abstract
169P - M-phase phosphoprotein 8 promotes gastric cancer growth and metastasis via p53/Bcl-2 and EMT-related signalling pathways
Presenter: Yizhuo Wang
Session: Poster display session
Resources:
Abstract
170P - Surgery alone versus surgery combined with Chemotherapy: Survival patterns among patients with fibrolamellar hepatocellular carcinoma
Presenter: Yasmine Ashraf
Session: Poster display session
Resources:
Abstract
171P - The clinical value of prognostic nutritional index in patients with anastomotic leakage after minimally invasive esophagectomy
Presenter: Yan Wang
Session: Poster display session
Resources:
Abstract
172P - Preoperative neutrophil‐to‐lymphocyte ratio (NLR) predicts recurrence after surgery in patient with pancreatic neuroendocrine neoplasm (PanNEN)
Presenter: Takayuki Miura
Session: Poster display session
Resources:
Abstract
173P - Cancer stem-like phenotypes including immune surveillance and its responsible genes in induced liver cancer stem-like cells
Presenter: Ryouichi Tsunedomi
Session: Poster display session
Resources:
Abstract